BCYC News and Press, Bicycle Therapeutics plc From 11/04/21

Bicycle Therapeutics (NASDAQ:BCYC): Q3 GAAP EPS of -$0.59 beats by $0.03. Revenue of $4.33M (+12.8% Y/Y) misses by $1.42M. Press Release For further details see: Bicycle Therapeutics EPS beats by $0.03, misses on revenue

Bicycle Therapeutics (NASDAQ:BCYC) announces that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD13...

- Announced interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial - First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Asso...

- BT7480 is the Company’s Fourth Product Candidate to Enter the Clinic in the Past Four Years - This is Bicycle’s First Immuno-oncology Asset to Enter the Clinic Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and diffe...

Ionis Pharmaceuticals (NASDAQ:IONS) saw its net loss increase ~122% in Q3 2021 year over year to ~$82M driven by costs related to restructured commercial operations and a boost in R&D expenses to advance its pipeline. R&D expenses increased 48% to $185M. Ionis said this figure include...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that an article highlighting preclinical data from BT7480, a tumor-targe...

Genentech exercised an option to initiate an additional program under the 2020 collaboration agreement Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bic...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the closing on Friday, October 15, 2021 of its underwritten public ...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the pricing of an underwritten public offering of 3,240,741 America...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that it has commenced an underwritten public offering of $125,000,0...